Pharmaniaga Bhd (XKLS:7081) Piotroski F-Score: 4 (As of Jul. 08, 2026) — Near Median


XKLS:7081 Pharmaniaga Bhd XKLS:7081
46 GF Score
Price RM1.22
GF Value RM0.74
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Pharmaniaga Bhd Piotroski F-Score?

Pharmaniaga Bhd XKLS:7081 -4.69% 46 Piotroski F-Score is 4 as of Jul. 08, 2026, which is at its 10-year median of 4.00. GuruFocus rates XKLS:7081 with a GF Score™ of 46/100 and a GF Value™ of RM0.74 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 112 Medical Distribution companies, Pharmaniaga Bhd ranks worse than 63.39% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Pharmaniaga Bhd has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Pharmaniaga Bhd's Piotroski F-Score or its related term are showing as below:

XKLS:7081' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 4   Max: 8
Current: 4

During the past 13 years, the highest Piotroski F-Score of Pharmaniaga Bhd was 8. The lowest was 2. And the median was 4.

Pharmaniaga Bhd  (XKLS:7081) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Pharmaniaga Bhd Piotroski F-Score Related Terms


Pharmaniaga Bhd Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Pharmaniaga Bhd's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharmaniaga Bhd Piotroski F-Score Chart

Pharmaniaga Bhd Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.00 2.00 5.00 7.00 4.00

Pharmaniaga Bhd Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.00 8.00 2.00 4.00 4.00

XKLS:7081 vs MCK, CAH, COR: Piotroski F-Score Comparison

For the Medical Distribution subindustry, Pharmaniaga Bhd's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharmaniaga Bhd Piotroski F-Score vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Pharmaniaga Bhd's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Pharmaniaga Bhd's Piotroski F-Score falls into.


XKLS:7081
46GF Score
Pharmaniaga Bhd XKLS:7081
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was 3.96 + 7.276 + 7.695 + 31.471 = RM50 Mil.
Cash Flow from Operations was -0.842 + -137.558 + 98.512 + -20.784 = RM-61 Mil.
Revenue was 926.864 + 1007.263 + 938.277 + 1178.524 = RM4,051 Mil.
Gross Profit was 90.253 + 95.299 + 96.995 + 128.524 = RM411 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(2139.198 + 2151.004 + 2396.687 + 2246.827 + 2357.398) / 5 = RM2258.2228 Mil.
Total Assets at the begining of this year (Mar25) was RM2,139 Mil.
Long-Term Debt & Capital Lease Obligation was RM110 Mil.
Total Current Assets was RM1,566 Mil.
Total Current Liabilities was RM1,707 Mil.
Net Income was 2.797 + 101.032 + 2.347 + 29.579 = RM136 Mil.

Revenue was 838.256 + 1029.822 + 926.442 + 1055.349 = RM3,850 Mil.
Gross Profit was 83.565 + 227.469 + 106.151 + 127.577 = RM545 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(2064.143 + 2079.595 + 2146.266 + 1992.306 + 2139.198) / 5 = RM2084.3016 Mil.
Total Assets at the begining of last year (Mar24) was RM2,064 Mil.
Long-Term Debt & Capital Lease Obligation was RM101 Mil.
Total Current Assets was RM1,358 Mil.
Total Current Liabilities was RM2,104 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Pharmaniaga Bhd's current Net Income (TTM) was 50. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Pharmaniaga Bhd's current Cash Flow from Operations (TTM) was -61. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=50.402/2139.198
=0.02356117

ROA (Last Year)=Net Income/Total Assets (Mar24)
=135.755/2064.143
=0.06576821

Pharmaniaga Bhd's return on assets of this year was 0.02356117. Pharmaniaga Bhd's return on assets of last year was 0.06576821. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Pharmaniaga Bhd's current Net Income (TTM) was 50. Pharmaniaga Bhd's current Cash Flow from Operations (TTM) was -61. ==> -61 <= 50 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=109.665/2258.2228
=0.04856252

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=101.337/2084.3016
=0.04861916

Pharmaniaga Bhd's gearing of this year was 0.04856252. Pharmaniaga Bhd's gearing of last year was 0.04861916. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=1566.067/1706.929
=0.91747636

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=1357.753/2104.4
=0.64519721

Pharmaniaga Bhd's current ratio of this year was 0.91747636. Pharmaniaga Bhd's current ratio of last year was 0.64519721. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Pharmaniaga Bhd's number of shares in issue this year was 1311.405. Pharmaniaga Bhd's number of shares in issue last year was 484.86. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=411.071/4050.928
=0.10147576

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=544.762/3849.869
=0.14150144

Pharmaniaga Bhd's gross margin of this year was 0.10147576. Pharmaniaga Bhd's gross margin of last year was 0.14150144. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=4050.928/2139.198
=1.89366669

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=3849.869/2064.143
=1.86511739

Pharmaniaga Bhd's asset turnover of this year was 1.89366669. Pharmaniaga Bhd's asset turnover of last year was 1.86511739. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+0+0+0+1+1+0+0+1
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Pharmaniaga Bhd has an F-score of 4 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 4 mean?
Pharmaniaga Bhd (XKLS:7081) has a Piotroski F-Score of 4 as of Jul. 08, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Pharmaniaga Bhd and its competitors. This is near median its historical median of 4.00. Over the past decade, Pharmaniaga Bhd's Piotroski F-Score has ranged from 2.00 to 8.00. According to the industry distribution chart, Pharmaniaga Bhd ranks #71 out of 112 companies in the Medical Distribution industry, placing it in the top 63.4%.
Is Pharmaniaga Bhd's Piotroski F-Score too high?
Pharmaniaga Bhd's current Piotroski F-Score of 4 is near median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 8.00. The Medical Distribution industry median Piotroski F-Score is 5.00. Pharmaniaga Bhd's value of 4 is 20% below this industry median. Based on the distribution chart, Pharmaniaga Bhd ranks #71 out of 112 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Pharmaniaga Bhd has a GF Score™ of 46/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Pharmaniaga Bhd's Piotroski F-Score compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Pharmaniaga Bhd ranks #71 out of 112 companies for Piotroski F-Score. This places Pharmaniaga Bhd in the lower half of its industry. The industry median Piotroski F-Score is 5.00. Pharmaniaga Bhd's value of 4 is 20% below this benchmark. Historically, Pharmaniaga Bhd's own Piotroski F-Score has ranged from 2.00 to 8.00 over the past decade. While the company's 10-year median is 4.00 vs. the industry median of 5.00, Pharmaniaga Bhd has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Medical Distribution company?
The median Piotroski F-Score among Medical Distribution companies is 5.00, based on 112 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pharmaniaga Bhd's current Piotroski F-Score of 4 is 20% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Pharmaniaga Bhd and its competitors. For the Medical Distribution industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharmaniaga Bhd's current Piotroski F-Score is 4, which is near median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmaniaga Bhd stock overvalued right now?
Based on GuruFocus' analysis, Pharmaniaga Bhd (XKLS:7081) is currently considered Significantly Overvalued. The stock's GF Value™ is RM0.74, compared to a current price of RM1.22 — trading 64.9% above its estimated fair value. The current Piotroski F-Score is 4, which is near median its 10-year median of 4.00 and 20% below the Medical Distribution industry median of 5.00. Pharmaniaga Bhd's overall GF Score™ is 46/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Pharmaniaga Bhd (XKLS:7081), the current Piotroski F-Score is 4 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pharmaniaga Bhd (XKLS:7081) Overvalued in 2026?

Based on GuruFocus' analysis, Pharmaniaga Bhd stock appears to be overvalued. The current stock price of RM1.22 is trading 64.9% above its estimated GF Value™ of RM0.74. GuruFocus considers Pharmaniaga Bhd to be Significantly Overvalued.

Key valuation signals for XKLS:7081:

  • Piotroski F-Score: 4 (near median its 10-year median of 4.00)
  • GF Value™: RM0.74 vs. price of RM1.22 (64.9% above fair value)
  • GF Score™: 46/100 with 8 warning signs
  • Industry Position: 20% below the Medical Distribution median (#71 of 112)

No single metric tells the full story. See the XKLS:7081 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Pharmaniaga Bhd Business Description

Address No. 7, Lorong Keluli 1B, Kawasan Perindustrian Bukit Raja, Seksyen 7, Selatan, Shah Alam, SGR, MYS, 40000
Pharmaniaga Bhd is engaged in the manufacture of pharmaceuticals and medical devices. The company is also involved in logistics and distribution. The group operates in three segments - Logistics and distribution, Manufacturing in Malaysia, and Manufacturing and distribution in Indonesia. Maximum revenue is generated by the logistics and distribution segment in Malaysia. The Logistics and distribution segment is engaged in distribution, trading and wholesaling of pharmaceutical and medical products as well as supply and installation of medical and hospital equipment in Malaysia.
46GF Score

Get the complete analysis for XKLS:7081

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

RM1.22
Price
RM0.74
GF Value